Core Viewpoints - AbbVie (ABBV) shares declined after the company announced a $3.5 billion impairment charge due to the failure of its experimental schizophrenia drug, emraclidine [1][3] - The impairment charge is related to the acquisition of Cerevel Therapeutics Holdings, from which AbbVie obtained emraclidine [1][3] - The Phase 2 trial of emraclidine did not meet primary endpoints, leading to a significant decrease in estimated future cash flows for the product [1][2][3] Financial Impact - AbbVie's shares fell 1% in recent trading but are up approximately 7% over the past year [2] - The $3.5 billion impairment charge reflects the financial impact of the drug's failure on the company's balance sheet [1][3] Drug Development Update - Emraclidine, an experimental medicine for treating schizophrenia in adults, failed to meet primary endpoints in its Phase 2 trial [1][3] - Following the trial results, AbbVie evaluated the impact, concluding a significant reduction in future cash flows for the product [2][3]

MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conferences. Each show brings together thousands of investors to attend workshops, presentations and seminars given by the nation's top financial experts. The company also offers exclusive seminars-at-sea, with the investment industry's leading partners. In addition, MoneyShow operates the award-winning, multimedia online community, Moneyshow.com and p ...

Company Analysis - AbbVie Inc (NYSE: ABBV) shows a 17% upside potential based on DCF model analysis [1] - The company maintains a fundamentally strong business with a diversified portfolio [1] - AbbVie's business is protected by long-term patents, providing stability and competitive advantage [1] Analyst Background - The analyst has 7 years of experience in the US stock market with a focus on portfolio management [1] - The analyst's IT background provides valuable perspective in analyzing technology stocks [1] - The analyst's approach emphasizes fundamental analysis and risk-reward balance in investment decisions [1] Investment Perspective - The analyst holds a beneficial long position in ABBV through stock ownership, options, or derivatives [2] - The analysis represents the analyst's independent opinion without external compensation [2] - The article aims to provide accessible insights for investors across experience levels [1]

NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medici ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.93%.For the last reported quarter, AbbVie came out with earnings of $3 per share versus ...

Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, is launching its third annual CoolMonth event to promote CoolSculpting® Elite, a leading non-surgical fat reduction treatment [1][2] - The event aims to encourage consumers to engage with CoolSculpting® experts and explore body contouring options, particularly as self-care resolutions are popular at the start of the year [1][2] - Promotions include a $300 discount for first-time users and a chance to win $10,000 through a sweepstakes for those who participate in the treatment [5][6] Company and Industry Overview - CoolSculpting® and CoolSculpting® Elite are FDA-cleared for treating visible fat bulges in various body areas, including the abdomen, thighs, and under the chin, for patients with a Body Mass Index (BMI) of ≤ 30 and ≤ 46 respectively [2][4] - The procedure is positioned as a solution for stubborn fat that does not respond to diet and exercise, enhancing the overall body contour for patients [2] - The CoolMonth event is designed to capitalize on the post-holiday period when interest in non-invasive body contouring treatments typically increases [2]

In an SEC filing, AbbVie (ABBV) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields. Unfortunately, stocks rarely offer ultrahigh yields unless there's concern about their ability to raise or maintain their dividend payouts.If you can't decide which dividend investing option you like best, I have some ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but you can prepare. Filling your portfolio with dividend-paying stocks that raise their quarterly payouts faster than the underlying inflation rate could even lead to extra spending cash.Medtronic (MDT 0.91%), Bristol ...

NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative me ...